FDA's top drug official told lawmakers Thursday (May 9) that firms falling under a proposed new category of compounding manufacturing should maintain a state pharmacy license to keep drug manufacturers from edging into this new class, as stakeholders further debated how to draw jurisdictional lines between compounding and manufacturing.
subscription required here
No comments:
Post a Comment